ann out re immunoxel, page-28

Absolute Rubbish : what conflicts, there aren?t any, they are partnerships in development and marketing and now have a world leading expert in intellectual property advisor from leading law firms in New York and Washington, DC and has substantial legal experience in prosecuting patents and corporate law. Press release re this from Immune Networks copy below :

And further confirmation for the need for a partnership for Global rights to develop and market Immunoxcel can be found in the press release of Immune Network Ltd. 14/2/2011.

The co-founder of Immunitor Dr. Aldar BOURINBAIAR, who were the original developers of Immunoxel, joined the board of Immune Networks IN Feb, 2011. Given his immaculate credentials and vast experience in the industry, particularly as an intellectual property advisor in leading law firms in New York and Washington, DC and has substantial legal experience in prosecuting patents and corporate law, would likely explain the necessity for the joint partnership and access to global rights to develop and market Immunoxel and it?s derivatives.

This bodes well that any such agreement should be water tight and give both parties access to profits from which ever forms of Immunoxel subsequently prove to be the most effective if not both as both continue their own development of it.

It further bodes very well that both Dr. Aldar BOURINBAIAR, and (Dr. Michael TOUNGE, who is now STI), were both involved in Immunoxel at Immunitor and given that Immunitor itself has successfully developed and marketed Atherosclerosis, Hep B, Hep C and HIV products, are at Phase 2 Tuberculosis trails, Phase 1 Trials for Cancer, Antimicrobial & Antifungal products and Preclinical on influenza, access to the knowledge and experience of these guys bodes very well for a likely successful outcome, whilst speeding up the development process by removing what would have otherwise likely been a legal impediment in that future development.

Press release reads :
2011-02-14 PR Immunitor CEO joins Board
posted Feb 14, 2011 9:50 PM by Allen Bain

Source: Immune Network Ltd
Immunitor CEO Joins Immune Network Board of Directors
VANCOUVER, British Columbia, Feb. 14, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF) is pleased to announce that a co-founder of Immunitor, Dr. Aldar Bourinbaiar, has joined Immune's board of directors. Immune Network is completing its acquisition of 50% of Immunitor Inc., a company which has global rights to a patented product called V5, clinically shown to be effective against hepatitis B, hepatitis C, and recently demonstrated as a potent immune adjunct for chemotherapeutic management of tuberculosis, including drug resistant MDR-TB and TB/HIV dual infection.

Immune Network's board of directors welcomes Dr. Aldar Bourinbaiar, the principal and CEO of Immunitor. Dr. Bourinbaiar is a doctor and a scientist (MD/PhD and PhD degrees from the University of Paris, France), and a businessman with 30 years of executive and operational experience combining basic science, biotech industry, and patent law.He has worked at various academic and business institutions in Mongolia, France, UK, Japan, Thailand and USA, and speaks five languages. Dr. Bourinbaiar has spent four years as an intellectual property advisor in leading law firms in New York and Washington, DC and has substantial legal experience in prosecuting patents and corporate law. He is inventor on eight US patents and has published over 120 articles and chapters in books. He is a member of the Editorial Board in several peer-reviewed professional journals in vaccine and virology fields. He has been involved in the biotech business since 1980 when he started working on commercial blood products derivatives (gamma-globulin, albumin, vaccines) at the Institute of Biochemistry of Blood in Mongolia. In 1987 he joined Hayashibara Biochemical Labs in Okayama, Japan ? a company that produces natural interferon and other important biotech products for cancer and other indications. Dr. Bourinbaiar is Thailand's regional representative elected by International Organization on Biotechnology and Bioengineering, Stockholm, Sweden. He is also an expert member of the Society of Industry Leaders, a division of Standard & Poor's and consultant for Reuters Insight, an independent research consultancy group owned by Reuters. Dr. Bourinbaiar is listed in International Who is Who Professionals, Marquis Who's Who, Marquis Who's Who in Asia, Who is Who Historical Society, and Cambridge's 2000 Outstanding Intellectuals of 21st Century.

Dr. Allen Bain, interim president, commented, "As we move ahead with the corporate issues in Immune Network, the clinical demonstration of V5 in several countries is continuing, thanks to the global outreach work of Dr. Bourinbaiar and his associates. Dr. Bourinbaiar's contribution to product registration and marketing strategy will be essential to the growth of Immune Network and implementation of V5 in the treatment of the millions of patients worldwide who may benefit from its use."

Dr. Bourinbaiar joins Drs. Bain and Alexander Zolotoy on the board of directors of Immune Network, and replaces outgoing director Mr. Don Benard.

The Immune Network Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8008

Safe Harbor Statement

The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.